Sign in
Taking peoplePhase 3

Tests KarXT for psychosis in people with Alzheimer's disease

Tests KarXT against placebo in people with Alzheimer's and psychosis.

Key facts

Who runs it
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Where
Buk-gu, Busan, Incheon, Seongnam-si, and Seoul, South KoreaSee the 8 sitesAlso in 13 other countries, 142 sites
Registry title
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Status
Recruiting
Phase
Phase 3
People taking part
500 people, planned
Started
28 Aug 2023
Expected to end
9 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • KarXT
  • Placebo
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 55 to 90 with mild to severe Alzheimer's disease who also have moderate to severe psychosis (hallucinations or delusions) caused by it.

Age
55 to 90 years
Sex
Men and women
Disease stage
Possible or probable Alzheimer's disease, with hallucinations or delusions for at least 2 months. Memory test (MMSE) score of 8 to 22.
Earlier treatment
Must not have had KarXT before. Must not have taken an experimental drug in the 3 months before screening.

Main reasons for not taking part

  • Psychosis mainly caused by something other than Alzheimer's disease
  • History of bipolar disorder, schizophrenia or schizoaffective disorder
  • Major depression with psychotic features in the past 12 months
  • History or high risk of urinary retention, gastric retention or narrow-angle glaucoma
  • Allergy to trospium chloride or KarXT ingredients, or serious side effects from trospium

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Is a male or female aged 55 to 90 years, inclusive, at Screening
  • Can understand the nature of the trial and protocol requirements and provide informed consent or assent before any study assessments are performed
  • Meets clinical criteria for Possible AD or Probable AD
  • Must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome, e.g., major stroke, neoplasm, subdural hematoma. If not available, a non-contrast brain MRI or non-contrast head CT must be done during Screening
  • Living at the same home or residential assisted-living facility for a minimum of 6 weeks before Screening
  • Have an identified study partner who should have daily contact (approximately 10 hours a week or more)
  • History of psychotic symptoms (meeting International Psychogeriatric Association criteria) (Cummings 2020) for at least 2 months prior to Screening
  • CGI-S scale with a score ≥ 4 at Screening and Baseline
  • AD subjects are required to have NPI-C: Hallucinations and Delusions (H+D) score of ≥ 6 AND meet at least 1 of the following criteria at Screening and Baseline:; Moderate to severe delusions, defined as NPI-C: Delusions domain score of ≥ 2 on 2 of the 8 items OR; Moderate to severe hallucinations, defined as NPI-C: Hallucinations domain score of ≥ 2 on 2 of the 7 items
  • MMSE score of 8 to 22, inclusive, at Screening

Who cannot take part

  • History of major depressive episode with psychotic features during the 12 months prior to Screening
  • Prior exposure to KarXT
  • Participation in another clinical study in which the subject received an experimental or investigational drug within 3 months before Screening or has participated in more than 2 clinical studies in the 12 months prior to Screening
  • Psychotic symptoms that are primarily attributable to a condition other than the AD causing the dementia
  • History of bipolar disorder, schizophrenia, or schizoaffective disorder
  • Significant or severe medical conditions including pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, cardiovascular, or oncologic disease or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results
  • History of hypersensitivity to KarXT excipients or trospium chloride
  • History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator
  • Experienced any significant adverse events (AEs) due to trospium
  • Other protocol-defined inclusion/exclusion criteria may apply

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 90 years old?
  • Has a doctor told you that you have Alzheimer's disease?
  • Do you have hallucinations or delusions caused by Alzheimer's disease?
  • Have you taken part in an earlier study of the same medicine (KarXT or ML-007C-MA) and finished it?
  • Has a doctor ever told you that you have bipolar disorder, schizophrenia or schizoaffective disorder?

Where in South Korea

Also in 13 other countries, 142 sites

  • Buk-gu, Daegu Gwang'yeogsiHospital not named in the registryNo longer taking part
  • BusanHospital not named in the registryNo longer taking part
  • Incheon, Incheon Gwang'yeogsiHospital not named in the registryNo longer taking part
  • Seongnam-siHospital not named in the registryNo longer taking part
  • Seongnam-si, GyeonggidoHospital not named in the registryNo longer taking part
  • Seoul, Seoul TeugbyeolsiHospital not named in the registryNo longer taking part
  • SeoulHospital not named in the registryNo longer taking part
  • SeoulHospital not named in the registryNo longer taking part

About the trial

What the trial wants to find out

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

Read full original descriptionShow less

The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

The 2 groups in the trial

  • KarXTTreatment being tested

    Xanomeline and Trospium Chloride Capsules

  • PlaceboPlacebo, for comparison

    Placebo capsules

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Plain-language title
Tests KarXT for psychosis in people with Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT06126224, who can take part
Record updated
16 October 2026